Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 3 (2006), Issue 4 (April)

  1. NKX3.1 is regulated by protein kinase CK2 in prostate tumor cells.
    Mol Cell Biol, 26(8): 3008-17. [Abstract] [Full-text]
  2. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
    J Lab Clin Med, 147(4): 174-81. [Abstract] [Full-text]
  3. Geometric and dosimetric evaluations of an online image-guidance strategy for 3D-CRT of prostate cancer.
    Int J Radiat Oncol Biol Phys, 64(5): 1596-609. [Abstract] [Full-text]
  4. Patient tolerance of rectal balloons in conformal radiation treatment of prostate cancer.
    Int J Radiat Oncol Biol Phys, 64(5): 1367-70. [Abstract] [Full-text]
  5. Anatomy-based inverse optimization in high-dose-rate brachytherapy combined with hypofractionated external beam radiotherapy for localized prostate cancer: comparison of incidence of acute genitourinary toxicity between anatomy-based inverse optimization and geometric optimization.
    Int J Radiat Oncol Biol Phys, 64(5): 1360-6. [Abstract] [Full-text]
  6. Prostate-specific antigen (PSA) bounce and other fluctuations: which biochemical relapse definition is least prone to PSA false calls? An analysis of 2030 men treated for prostate cancer with external beam or brachytherapy with or without adjuvant androgen deprivation therapy.
    Int J Radiat Oncol Biol Phys, 64(5): 1355-9. [Abstract] [Full-text]
  7. Urine markers as possible tools for prostate cancer screening: review of performance characteristics and practicality.
    Clin Chem, 52(4): 562-73. [Abstract] [Full-text]
  8. Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells.
    Biochem Biophys Res Commun, 343(3): 848-56. [Abstract] [Full-text]
  9. Mortality from all cancers and lung, colorectal, breast and prostate cancer by country of birth in England and Wales, 2001-2003.
    Br J Cancer, 94(7): 1079-85. [Abstract] [Full-text]
  10. New approaches in hormone refractory prostate cancer.
    Am J Clin Oncol, 29(2): 196-201. [Abstract] [Full-text]
  11. Insulin sensitivity during combined androgen blockade for prostate cancer.
    J Clin Endocrinol Metab, 91(4): 1305-8. [Abstract] [Full-text]
  12. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    BMC Cancer, 6: 60. [Abstract] [Full-text]
  13. Vascular endothelial growth factor production in human prostate cancer cells is stimulated by overexpression of platelet 12-lipoxygenase.
    Prostate, 66(7): 779-87. [Abstract] [Full-text]
  14. Meta-analysis of association of rare mutations and common sequence variants in the MSR1 gene and prostate cancer risk.
    Prostate, 66(7): 728-37. [Abstract] [Full-text]
  15. Methylation of the ASC gene promoter is associated with aggressive prostate cancer.
    Prostate, 66(7): 687-95. [Abstract] [Full-text]
  16. Overexpression of ecto-protein kinases in prostasomes of metastatic cell origin.
    Prostate, 66(7): 675-86. [Abstract] [Full-text]
  17. Regulation of prostate 5alpha-reductase-2 gene expression and prostate weight by dietary fat and caloric intake in the rat.
    Prostate, 66(7): 738-48. [Abstract] [Full-text]
  18. In vivo magnetic resonance volumetric and spectroscopic analysis of mouse prostate cancer models.
    Prostate, 66(7): 708-17. [Abstract] [Full-text]
  19. Complete regression of experimental prostate cancer in nude mice by repeated hyperthermia using magnetite cationic liposomes and a newly developed solenoid containing a ferrite core.
    Prostate, 66(7): 718-27. [Abstract] [Full-text]
  20. PI3K/Akt signaling regulates p27(kip1) expression via Skp2 in PC3 and DU145 prostate cancer cells, but is not a major factor in p27(kip1) regulation in LNCaP and PC346 cells.
    Prostate, 66(7): 749-60. [Abstract] [Full-text]
  21. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Cancer, 106(8): 1708-14. [Abstract] [Full-text]
  22. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Cancer, 106(8): 1715-21. [Abstract] [Full-text]
  23. Predictive validity of five comorbidity indices in prostate carcinoma patients treated with curative intent.
    Cancer, 106(8): 1804-14. [Abstract] [Full-text]
  24. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms.
    Endocrinology, 147(5): 2112-21. [Abstract] [Full-text]
  25. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
    Int J Radiat Oncol Biol Phys, 65(1): 304-7. [Abstract] [Full-text]
  26. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
    Int J Radiat Oncol Biol Phys, 65(1): 291-303. [Abstract] [Full-text]
  27. An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: implications for radioresistance.
    Int J Radiat Oncol Biol Phys, 65(1): 91-9. [Abstract] [Full-text]
  28. Effect of combined treatment with salvage radiotherapy plus androgen suppression on quality of life in patients with recurrent prostate cancer after radical prostatectomy.
    Int J Radiat Oncol Biol Phys, 65(1): 78-83. [Abstract] [Full-text]
  29. Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.
    Int J Radiat Oncol Biol Phys, 65(1): 65-72. [Abstract] [Full-text]
  30. Prognostic value of PSA nadir < or =4 ng/mL within 4 months of high-dose radiotherapy for locally advanced prostate cancer.
    Int J Radiat Oncol Biol Phys, 65(1): 73-7. [Abstract] [Full-text]
  31. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 65(1): 84-90. [Abstract] [Full-text]
  32. Rising prostate-specific antigen values during neoadjuvant androgen deprivation therapy: The importance of monitoring.
    Int J Radiat Oncol Biol Phys, 65(1): 59-64. [Abstract] [Full-text]
  33. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891.
    J Clin Oncol, 24(12): 1868-76. [Abstract] [Full-text]
  34. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial.
    J Natl Cancer Inst, 98(8): 529-34. [Abstract] [Full-text]
  35. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
    J Natl Cancer Inst, 98(8): 516-21. [Abstract] [Full-text]
  36. Differentially expressed genes in the prostate cancer cell line LNCaP after exposure to androgen and anti-androgen.
    Cancer Genet Cytogenet, 166(2): 130-8. [Abstract] [Full-text]
  37. SAHA-sensitized prostate cancer cells to TNFalpha-related apoptosis-inducing ligand (TRAIL): mechanisms leading to synergistic apoptosis.
    Int J Cancer, 119(1): 221-8. [Abstract] [Full-text]
  38. Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
    Cancer, 106(9): 1917-24. [Abstract] [Full-text]
  39. Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.
    Cancer, 106(9): 1865-74. [Abstract] [Full-text]
  40. Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro.
    Prostate, 66(8): 867-75. [Abstract] [Full-text]
  41. GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
    Prostate, 66(8): 886-94. [Abstract] [Full-text]
  42. In vitro and in vivo prodrug therapy of prostate cancer using anti-gamma-Sm-scFv/hCPA fusion protein.
    Prostate, 66(8): 858-66. [Abstract] [Full-text]
  43. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model.
    Prostate, 66(8): 831-8. [Abstract] [Full-text]
  44. Induction of apoptosis and inhibition of NF-kappaB activation in human prostate cancer cells by the cis-9, trans-11 but not the trans-10, cis-12 isomer of conjugated linoleic acid.
    Prostate, 66(8): 839-46. [Abstract] [Full-text]
  45. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
    Prostate, 66(8): 847-57. [Abstract] [Full-text]
  46. Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial.
    Prostate, 66(8): 811-21. [Abstract] [Full-text]
  47. Renin-angiotensin system is an important factor in hormone refractory prostate cancer.
    Prostate, 66(8): 822-30. [Abstract] [Full-text]
  48. IGF-I secretion by prostate carcinoma cells does not alter tumor-bone cell interactions in vitro or in vivo.
    Prostate, 66(8): 789-800. [Abstract] [Full-text]
  49. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers.
    Prostate, 66(8): 801-10. [Abstract] [Full-text]
  50. Diagnostic utility of a p63/alpha-methyl coenzyme A racemase (p504s) cocktail in ambiguous lesions of the prostate upon needle biopsy.
    BJU Int, 97(5): 1109-15. [Abstract] [Full-text]
  51. Incidental acute prostatic inflammation is associated with a lower percentage of free prostate-specific antigen than other benign conditions of the prostate: a prospective screening study.
    BJU Int, 97(5): 1039-42. [Abstract] [Full-text]
  52. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    BJU Int, 97(5): 985-91. [Abstract] [Full-text]
  53. Laparoscopic radical prostatectomy: minimum 3-year follow-up of the first 100 patients in the UK.
    BJU Int, 97(5): 981-4. [Abstract] [Full-text]
  54. Third-generation cryotherapy for prostate cancer in the UK: a prospective study of the early outcomes in primary and recurrent disease.
    BJU Int, 97(5): 969-74. [Abstract] [Full-text]
  55. Health-related quality of life and satisfaction with care among older men treated for prostate cancer with either radical prostatectomy or external beam radiation therapy.
    BJU Int, 97(5): 955-62. [Abstract] [Full-text]
  56. Clinical trials in patients with biochemically relapsed prostate cancer.
    BJU Int, 97(5): 905-10. [Abstract] [Full-text]
  57. Patterns of practice in the management of prostate cancer: results from multidisciplinary surveys of clinicians in Australia and New Zealand in 1995 and 2000.
    BJU Int, 97(5): 975-80. [Abstract] [Full-text]
  58. Testosterone and erectile function recovery after radiotherapy and long-term androgen deprivation with luteinizing hormone-releasing hormone agonists.
    BJU Int, 97(5): 963-8. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

The Prostate Cancer Treatment Book

The Prostate Cancer Treatment Book